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With just 225 beds to treat a population
drainage area of 1.5 million people,
much of it lawless gangland, the
beleaguered staff of the struggling Cape
Flats GF Jooste Hospital were strangely
buoyant on 1 December  last year.
It wasn’t just the presence of ex-
president Nelson Mandela in a
steaming summer marquee erected to
celebrate the launch of his Foundation
and the South African Medical
Association’s Tshepang AIDS treatment
campaign on World AIDS day. That
didn’t fully explain the sustained, even
riotous applause from staffers when
their Medical Superintendent, Dr
Jeremy Venter, saluted the passion with
which they kept their hospital
functioning and announced sustained
antiretroviral (ARV) treatment for their
patients. Venter said the ARV drug
therapy introduced through SAMA’s
innovative public/private Tshepang
campaign would ‘definitely decrease’
hospital admissions by reducing
opportunistic infections and thus the
strain of an almost unbearable
workload. Chosen for its central
geographical location and its 15 000
patients needing ARVs (10% of the HIV-
positive population in the area), GF
Jooste Secondary Hospital will apply
the fruits of the pioneering work of
Medicins Sans Frontieres (MSF) in
nearby Khayelitsha — well ahead of the
much-vaunted national ARV roll-out.
This will help keep the Western Cape,
according to its Premier Marthinus van
Schalkwyk, well ahead of all other
provinces with 15 ARV sites up and
running by the end of February this
year.
SAMA, the Nelson Mandela
Foundation and the Western Cape
Government collaborated to get the
additional GF Jooste Hospital ARV site
off the ground, bringing to eight the
number of ARV sites in the province by
1 December. It is the first partnership
between government and private
organisations to provide ARVs.
Conceived 11 months ago when
national government was still reticent to
create and publicly commit itself to a
specific ARV roll-out plan, the
SAMA/NMF ART plan consists of
setting up two sites in every province to
treat  people in stages three and four of
AIDS. Mandela handed over a R5
million cheque to SAMA chairman, Dr
Kgosi Letlape, half of the money
pledged by his Foundation to the
Tshepang Trust when it was first
launched by SAMA last year. All R10
million will go towards sustaining the
GF Jooste ARV programme over the
first three years.
Launching SAMA’s Tshepang
Campaign in the Western Cape makes
practical sense. The province has the
most progressive HIV/AIDS planning
(plus the best infrastructure), and had
achieved a 100% roll-out of prevention
of mother-to-child infection in its ante-
natal clinics by the beginning of last
year (2003).
According to Van Schalkwyk, the
latest AIDS target is an 83% saturation
of the Western Cape’s ARV-qualifying
population within five years. He and Dr
Fareed Abdullah,  the Western Cape
AIDS chief, recently returned from
Geneva bearing a handy R455 million
‘bonsella’ from the Global AIDS Fund.
Their bid was part of a national,
province-by-province bid for Global
funding. The other provinces that made
the last bid deadline are still battling to
revise their budget details to meet strict
Global Fund criteria. This will be added
to their share of Finance Minister Trevor
Manuel’s R1.9 billion AIDS budget,
much of it to be used for the ARV
campaign.
Professor Gary Maartens, Head of
Infectious Diseases as Groote Schuur
Hospital, who conceptualised the
training component of the regional
launch site, believes GF Jooste will
eventually see an 80% reduction in HIV
opportunistic infections. However, he
cautioned, ‘We’ll only treat about 300
people in the first year and you won’t
see an impact on admissions in the first
year or two’. He believes that once the
additional provincial ART programme
rolls out, and depending on how
quickly it is accelerated, the reduction in
infections will be noticeable within
three years.
The GF Jooste clinicians will start on
the more complicated AIDS cases first
and once they are stabilised, move them
out to private and public clinics,
depending on expertise and availability.
‘We want to get them through the
difficult first 6 - 12 weeks and use this
as a training vehicle to make it a centre
of excellence,’ Maartens added.
The Tshepang /GF Jooste site will
initially be staffed by four fully ARV-
trained doctors, two adherence
counsellors, a full-time nurse and an
administrative clerk. Where
appropriate, this team will refer patients
to doctors in private practice  or at
Venter said the ARV drug
therapy introduced through
SAMA’s innovative
public/private Tshepang
campaign would ‘definitely
decrease’ hospital admissions
by reducing opportunistic
infections and thus the strain
of an almost unbearable
workload.
Professor Gary Maartens, Head of Infectious
Diseases at Groote Schuur Hospital, Dr Eula
Mothibi, Chief of GF Jooste’s HIV/AIDS Unit
and Dr Kgosi Letlape, SAMA chairperson.
SAMA LEADS THE WAY WITH ARV ROLL-OUT
January 2004, Vol. 94, No. 1  SAMJ
IZINDABA
18
community health centres, who have
been trained in ART treatment at GF
Jooste or by MSF in Khayelitsha (or
those who have taken SAMA’s
Foundation for Professional
Development AIDS course).
Private practitioners will be paid by
the Tshepang Trust for their services.
Treatment Action Campaign (TAC)
chairman, Zackie Achmat, said that
many of his colleagues ‘would rather
die than’ attend GF Jooste because of its
reputation for lack of service and
overworked staff. However, he firmly
pledged TAC support ‘to make this the
premier treatment site’. Dr Eula
Mothibi, chief of the hospital’s AIDS
unit, and the on-site pharmacist,
Mohamed Sonday, said they intended
enrolling local religious leaders,
referring doctors and civic leaders in
their catchment area into preaching the
benefits of ARV. Said Mothibi, ‘Often
people come in in the terminal stages
and we could do very little for them up
to now’.
Dr Stan Leketi, executive chairman of
Bophelo Lifeworks, which helped
SAMA develop its ARV roll-out
strategy, told SAMJ that he had seen
patients recover and lead healthy lives
with ARV intervention at a CD4 cell
count level as low as 7. The national
government’s ARV plan, drawn up by a
task team of 16 experts from the World
Health Organisation, the Clinton
Foundation, the
DOH and led by
the Medical
Research
Council’s Dr
Anthony Mbewu,
wants one
treatment site in
each of the
country’s 53
health districts.
Within five
years it wants
access for all who
need ARV in their
own municipal
areas. The national
government
commitment is to
try to treat all 1.4 million people who
are expected to clinically require ARV
by 2008 at a total cost of R4.4 billion in
that year. With staff capacity at a
premium, a nursing and doctor
shortage and immigration trends
climbing in the face of what health care
workers view as legislation hostile to
the continued practice of their
profession, delivering the goods will be
a tall order. Although the national
operational plan has set aside R500
million for recruitment and retention of
health care workers, this money has
become stuck in the collective
bargaining process.
According to the government’s task
team report, ARV conservatively allows
an extension of 3.6 - 4.4 years of
relatively illness-free life when
compared  with non-ARV treatment.
With a 20% ARV coverage scenario,
close to a million additional years of life
would be saved by 2010, while 100%
ARV coverage could save an additional
5 million years of life by 2010.
ART, when added to standard care,
reduced the cost of each additional year
of life gained by between R2 000 and
R3 000. Without ART the report
estimates that 1.8 million children will
be orphaned between 2003 and 2010.
With 20% ART coverage this total
would be reduced by 140 000 children
and with 100% ART coverage, by 
860 000 children.
Under all scenarios, a comprehensive
prevention programme would cost an
additional R550 - R570 million per year
for the rest of the decade (in the absence
of fundamental technological
developments, such as the discovery of
an effective and affordable vaccine).
Asked about serious concerns around
non-compliance of drug use leading to
drug resistance strains in the
population, an MSF spokesman in the
Western Cape said that no patients had
been lost to follow up. Monitoring in
Khayelitsha had shown that after one
year on ART, 90% of patients were
taking at least 95% of their tablets and
that 90% of patients had reached
undetectable viral loads after three
months, with a dramatic decrease in the
frequency of opportunistic infections.
ARV had also had a ‘hugely positive’
affect on openness about HIV/AIDS in
preventing new infections, decreasing
stigma and discrimination and fuelling
prevention efforts.
Mandela said he hoped the
public/private partnership entered into
by the Tshepang Trust would be
replicated across the country. ‘Health
should not be a question of income. It is
a fundamental human right. We must
give people hope,’ he added.
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